Distribution And Emergence Of Chloroquine-Resistant Plasmodium Vivax

Authors

  • Kanchana Rungsihirunrat College of Public Health Sciences, Chulalongkorn University, Bangkok, Thailand
  • Jiraporn Kuesap Center of Excellence in Drug Discovery and Development (TCEDDD), Thammasat University, Pathumthani, Thailand
  • Wanna Chaijaroenkul Center of Excellence in Drug Discovery and Development (TCEDDD), Thammasat University, Pathumthani, Thailand
  • Kesara Na-Bangchang Center of Excellence in Drug Discovery and Development (TCEDDD), Thammasat University, Pathumthani, Thailand

Keywords:

Plasmodium vivax, chloroquine resistance, Distribution

Abstract

Plasmodium vivax is the second most geographically widespread human malaria parasite. The global burden of P. vivax malaria is approximately 70-80 million cases annually. Chloroquine given together with primaquine is currently the first-line treatment for P. vivax.  P. vivax resistance to chloroquine has however been reported in several endemic areas, particularly Southeast Asia, the area with the greatest P. vivax burden. Emergence of chloroquine-resistant P. vivax (CRPV) imposes a significant impact on the control strategies and treatment policies in these endemic regions.

Downloads

How to Cite

Rungsihirunrat, K., Kuesap, J., Chaijaroenkul, W., & Na-Bangchang, K. (2017). Distribution And Emergence Of Chloroquine-Resistant Plasmodium Vivax. Journal of Health Research, 27(1), 57–65. Retrieved from https://he01.tci-thaijo.org/index.php/jhealthres/article/view/85760

Issue

Vol. 27 No. 1: January - February 2013

Section

REVIEW ARTICLE